Clinical trial NCT03690739: Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
Official title: Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Recurrent Ovarian Carcinoma
Keywords: Symptom Benefit
Lead sponsor: AGO Research GmbH
Sponsor class: INDUSTRY
First posted: 2018-10-01
Enrollment: 9
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.

Detailed description: Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified below:

Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)

Eligibility criteria: Inclusion Criteria:

1. Females aged ≥ 18 years at time of signing informed consent form.
2. Histologically proven diagnosis of cancer of the ovary, the fallopian tube or primary peritoneal cancer.
3. Measurable or non-measurable disease (according RECIST v1.1) or CA-125 assessable disease (according GCIG criteria) or histologically proven diagnosis of relapse.
4. Platinum-treatment free interval (TFIp) \> 6 months prior to cycle 1 day 1 of reinduction therapy.
5. Disease stabilization without remission or progression ac-cording to RECIST or GCIG criteria after three cycles of platinum-based chemotherapy for recurrent disease.
6. Symptomatic disease at time of baseline abdominal/GI symptom scale score \>15 (EORTC QLQ-OV28)
7. Completion of EORTC QLQ-OV28 at Baseline within 7 days prior to treatment start.
8. Patients should have received previously a taxane derivative.
9. ECOG performance status ≤ 2.
10. Life expectancy of at least 12 weeks.
11. Adequate bone marrow, renal and hepatic function defined as:

    * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
    * Platelet count ≥ 100 x 10\^9/L
    * Hemoglobin ≥ 9.0 g/dL
    * Serum creatinine ≤1.5 mg/dL (≤ 132.6 µmol/L) or creatinine clearance ≥ 60 mL/min
    * Creatine phosphokinase (CPK) ≤ 2.5 x ULN
    * Serum aspartate aminotransferase (AST, SGOT) or alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN (≤ 5 x ULN in the presence of liver metastases)
    * Alkaline phosphatase (ALP) ≤ 2.5 ULN
    * Serum bilirubin ≤ ULN
    * Albumin ≥ 25 g/l
12. Participation in an informed consent discussion with the appropriate trial-related health care representative, full understanding of the implications and constraints of the protocol, and provision of written informed consent prior to the commencement of the trial-related procedures.
13. Geographically accessibility for treatment and follow-up.
14. For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain from heterosexual inter-course) or use a contraceptive method with a failure rate of \< 1 per-centage per year during the treatment period and for at least six months after administration of the last dose of chemo-therapy. A woman is considered to be of childbearing po-tential if she is postmenarcheal, has not reached a post-menopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fal-lopian tubes, and/or uterus). Examples of contraceptive methods with a failure rate of \< 1 percentage per year in-clude but are not limited to bilateral tubal ligation and/or oc-clusion, male sterilization, and intrauterine devices, and nor-mal and low dose combined oral pill plus male condom or Cerazette (desogestrel) plus male condom. Cerazette is currently the only highly efficacious progesterone based pill. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation meth-ods) and withdrawal are not acceptable methods of contra-ception.

Exclusion Criteria:

1. Ovarian tumors of low malignant potential (e.g. borderline tumors).
2. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Müllerian tumors).
3. Patients with an objective response in terms of a partial or complete remission or alternatively progressive disease ac-cording to RECIST or GCIG criteria after three cycles of platinum-based reinduction chemotherapy.
4. Patients who have received previous radiotherapy for ovarian cancer.
5. History of congestive heart failure (NYHA classification \> 2, even if medically con-trolled).
6. History of myocardial infarction within the last six months (documented or by electrocardiogram).
7. History of atrial or ventricular arrhythmias.
8. Impaired liver function, hyperbilirubinemia, Serum creatinine \>1.5 mg/dL or \> 132.6 μmol/L or creatinine clearance \< 60 mL/min, left ventricular ejection fraction \< 45 %.
9. Severe active or uncontrolled infection.
10. Concurrent severe medical problems unrelated to malignancy, which would significantly limit full compliance with the trial or expose the patient to extreme risk or decreased life expectancy.
11. Patients with known hypersensitivity to the active substance or their compounds related to trabectedin or PLD and patients with known hypersensitivity to one of active substances or one of their compounds used in platinum-based chemotherapy as described in the Summaries of Medicinal Products.
12. Patients with potential risks according to contraindication, warnings or interactions of the used chemotherapeutic agents as stated in the SmPCs are not eligible for participation in this trial.
13. Patients with contraindication regarding CT or MRI (only in case of contrast allergy) are excluded.
14. Women of childbearing potential (WOCBP) not using highly effective contraceptive methods.
15. Pregnancy or breast-feeding.

Primary outcomes:
measure: Symptom Benefit Rate
timeFrame: from Baseline to 8 or 9 weeks after randomization, assessed at each visit
Secondary outcomes:
measure: Time until definitive deterioration (TUDD )
timeFrame: from Baseline until 24 months after randomization, assessed up to 54 months at each visit
measure: Progression-free survival (PFS)
timeFrame: PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first), assessed up to 54 months
measure: Progression-free survival (PFS) rate at 6 months
timeFrame: PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first) after six months
measure: Response Rate (RR)
timeFrame: from randomization until patients achieving complete response (CR) or partial response (PR) as best overall response, assessed up to 54 months
measure: Global Health Status
timeFrame: from baseline to end of treatment, assessed up to 54 months at each visit
measure: Overall Survival (OS)
timeFrame: OS is defined as the time from randomization to death from any cause, assessed up to 54 months
Other outcomes:
Locations:
city: Aschaffenburg
country: Germany
facility: Klinikum Aschaffenburg-Alzenau
state: Bayern
city: Bad Homburg
country: Germany
facility: Hochtaunus-Kliniken
city: Bamberg
country: Germany
facility: Sozialstiftung Bamberg
city: Bergisch Gladbach
country: Germany
facility: Evangelisches Krankenhaus Bergisch Gladbach
city: Berlin
country: Germany
facility: Charité - Universitätsmedizin Berlin
city: Bonn
country: Germany
facility: Universitätsfrauenklinik Bonn
city: Bottrop
country: Germany
facility: Schwerpunktpraxis für Onkologie / Hämatologie
city: Braunschweig
country: Germany
facility: Frauenärzte Casparistraße
city: Dresden
country: Germany
facility: Universitätsklinikum Carl Gustav Carus
city: Essen
country: Germany
facility: Evang. Kliniken Essen-Mitte
city: Frankfurt
country: Germany
facility: Agaplesion Markus Krankenhaus
city: Greifswald
country: Germany
facility: Universitätsmedizin Greifswald
city: Hamburg
country: Germany
facility: Mammazentrum Hamburg am Krankenhaus Jerusalem
city: Itzehoe
country: Germany
facility: Klinikum Itzehoe
city: Karlsruhe
country: Germany
facility: ViDia Christliche Kliniken Karlsruhe
city: Ludwigsburg
country: Germany
facility: Klinikum Ludwigsburg
city: Magdeburg
country: Germany
facility: Klinikum Magdeburg
city: Mainz
country: Germany
facility: Katholisches Klinikum Mainz
city: Mannheim
country: Germany
facility: Universitätsfrauenklinik Mannheim
city: Memmingen
country: Germany
facility: Klinikum Memmingen
city: München
country: Germany
facility: Klinikum rechts der Isar
city: Neumarkt
country: Germany
facility: Kliniken des Landkreises Neumarkt
city: Oldenburg
country: Germany
facility: Universitätsklinik für Innere Medizin, Onkologie und Hämatologie
city: Potsdam
country: Germany
facility: Klinikum Ernst von Bergmann
city: Rotenburg
country: Germany
facility: Agaplesion Diakonieklinikum Rotenburg
city: Saalfeld
country: Germany
facility: Thüringen Kliniken "Georgius Agricola"
city: Stralsund
country: Germany
facility: g.Sund Gyn. Kompetenzzentrum
city: Torgau
country: Germany
facility: Kreiskrankenhaus "Johann Kentmann"
city: Wiesbaden
country: Germany
facility: Helios Dr. Horst Schmidt Kliniken
Study officials:
affiliation: Mammazentrum am Krankenhaus Jerusalem, Hamburg
name: Felix Hilpert, MD, PhD
role: STUDY_CHAIR
References: